On June 24, 2025, MIRA Pharmaceuticals, Inc. announced the acquisition of SKNY Pharmaceuticals, which is developing the oral drug SKNY-1 for weight loss and smoking cessation. Preclinical data shows SKNY-1 may effectively target metabolic syndrome without the psychiatric side effects seen in previous treatments.